Showing results (51-60 of 79) with videos related to
Sort By:
Pageof 8
Blood|April 9, 2005
Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantationScott R Solomon, Stephan Mielke, Bipin N Savani, et al.Blood|October 27, 2023
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001Jeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.Blood|December 21, 2022
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM studyJeremy S Abramson, Scott R Solomon, Jon Arnason, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2023
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design StudyMichael Wang, Tanya Siddiqi, Leo I Gordon, et al.Lancet (London, England)|June 19, 2022
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialManali Kamdar, Scott R Solomon, Jon Arnason, et al.The Lancet. Haematology|June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialJeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.Blood|June 4, 2026
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCLJeremy S Abramson, Tanya Siddiqi, Leo I Gordon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2025
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM StudyManali Kamdar, Scott R Solomon, Jon Arnason, et al.Lancet (London, England)|September 5, 2020
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyJeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.The New England Journal of Medicine|February 10, 2023
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.Pageof 8